Form 4: Keros Therapeutics Director Sells Shares Under 10b5-1 Plan

Keros Therapeutics Director Julius Knowles sold 2,625 shares of common stock for $10.73 per share under a pre-arranged trading plan.

Summary

• Julius Knowles, a Director of Keros Therapeutics, Inc. (KROS), disposed of 2,625 shares of common stock.
• The transaction occurred on June 4, 2026, at a weighted average price of $10.73 per share.
• The shares were sold in multiple transactions ranging from $10.61 to $10.89.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Knowles on December 5, 2025.
• Following the transaction, Mr. Knowles directly beneficially owns 10,958 shares of common stock.
• Mr. Knowles also indirectly beneficially owns 150,047 shares through Partners Innovation Fund, LLC (PIF I) and 102,233 shares through Partners Innovation Fund II, L.P. (PIF II).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative signal. While the sale was pre-planned under a 10b5-1 plan, insider selling by a director can still suggest a move to diversify or a less bullish outlook, even if not directly tied to immediate company performance.

Negatives

• A director's sale of shares, even under a pre-arranged plan, can sometimes be interpreted by the market as a lack of confidence or a move to diversify holdings.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider sales, even when executed under a Rule 10b5-1 plan, are closely watched by investors. While a 10b5-1 plan indicates a pre-scheduled transaction rather than a reaction to immediate news, the market often scrutinizes such sales for potential signals regarding an insider's long-term view of the company's prospects or valuation.

Related Party Transactions

• Julius Knowles indirectly holds shares through Partners Innovation Fund, LLC (PIF I) and Partners Innovation Fund II, L.P. (PIF II). Mr. Knowles is a partner of Partners GP I and Partners GP II, the ultimate general partners of PIF I and PIF II, respectively, and may be deemed to share voting and investment power over these shares.

Stakeholder Impact

• Shareholders may interpret the director's sale as a potential signal regarding the company's future prospects, which could impact investor confidence.

Key Dates

Recommendation

The sale by a director, even under a Rule 10b5-1 plan, does not provide a strong positive catalyst for the stock. While not an immediate red flag due to the pre-planned nature, it suggests a director is taking profits or diversifying, rather than increasing their stake. Investors should maintain a 'hold' position and monitor future company developments and insider activity.

Keywords

Keros Therapeutics, KROS, Insider Trading, Form 4, Director, Stock Sale, 10b5-1 Plan